Form 4: Cryo-Cell Co-CEO Portnoy Boosts Stake with Open Market Buys
Insider Transaction Report
Cryo-Cell International Co-CEO David Portnoy increased his direct beneficial ownership of common stock through open market purchases in mid-November 2025.
Summary
- David Portnoy, Chairman and Co-CEO of Cryo-Cell International Inc. (CCEL), a Director, and a 10% Owner, reported multiple open market purchases of common stock.
- On November 17, 2025, Mr. Portnoy acquired 1,429 shares of common stock at a price of $4.00 per share.
- On November 18, 2025, an additional 640 shares were purchased at $4.09 per share.
- On November 19, 2025, 1,921 shares were acquired at a weighted average price of $4.08 per share.
- Following these transactions, Mr. Portnoy directly beneficially owns 846,540 shares of common stock.
- Mr. Portnoy also holds significant indirect beneficial ownership through various entities and accounts, including 161,833 shares by PartnerCommunity, Inc., 57,306 shares by uTIPu, Inc., 164,182 shares by 401K, 268,878 shares by IRA, 107,403 shares by Spouse, 33,874 shares as Custodian for sons, and 59,027 shares by Mayim Limited Partnership.
- He holds several stock options with varying exercise prices and expiration dates, totaling 530,000 underlying shares, some with specific vesting schedules or price targets (e.g., $25.00 per share for 280,000 options).
- The transactions were made pursuant to a Rule 10b5-1(c) plan.
Sentiment
Score: 8
Explanation: The Co-CEO's direct open market purchases of company stock signal strong confidence in the company's future prospects and valuation, which is a significant positive indicator for investors.
Positives
- The Chairman and Co-CEO, David Portnoy, made direct open market purchases of company stock, signaling strong insider confidence in the company's current valuation and future prospects.
- The purchases were made at prices ranging from $4.00 to $4.09 per share, indicating management's belief in the stock's value at these levels.
- The transactions were executed under a Rule 10b5-1(c) plan, suggesting a pre-planned investment strategy.
Future Outlook
NA
Industry Context
This Form 4 filing details an insider's personal trading activity and does not provide broader industry context or trends. However, insider buying can be a signal of management's perception of the company's position within its industry.
Stakeholder Impact
- Shareholders may view the Co-CEO's increased stake as a positive sign of management's belief in the company's value, potentially boosting investor confidence.
- Employees may interpret the insider buying as a sign of stability and positive future outlook for the company.
Key Dates
| Date | Description |
|---|---|
| 08/30/2019 | Grant date for 26,243 stock options with an exercise price of $7.53, expiring 08/30/2029. |
| 12/20/2019 | Grant date for 23,636 stock options with an exercise price of $7.28, expiring 12/20/2029. |
| 12/22/2021 | Grant date for 280,000 stock options with an exercise price of $12.27, expiring 12/22/2028. These options vest immediately if the common stock price reaches $25.00 per share during the seven-year option term. |
| 12/23/2022 | Grant date for 50,000 stock options with an exercise price of $4.30, expiring 12/23/2027. |
| 01/03/2023 | Grant date for 50,000 stock options with an exercise price of $4.77, expiring 01/03/2028. 8,750 options vested upon issuance, 8,749 options vest on 1/2/2024, 21,000 options vest on 1/2/2025, and 11,501 options vest on 1/2/2026. |
| 12/22/2023 | Grant date for 50,000 stock options with an exercise price of $6.47, expiring 12/22/2028. These options vest 1/3 upon issuance, 1/3 on December 22, 2024, and 1/3 on December 22, 2025. |
| 01/02/2024 | Vesting date for 8,749 stock options granted on 01/03/2023. |
| 12/22/2024 | Vesting date for 1/3 of stock options granted on 12/22/2023. |
| 01/21/2025 | Grant date for 50,000 stock options with an exercise price of $8.08, expiring 01/21/2030. These options vest 1/3 upon issuance, 1/3 on January 21, 2026, and 1/3 on January 21, 2027. |
| 01/02/2025 | Vesting date for 21,000 stock options granted on 01/03/2023. |
| 11/17/2025 | Acquisition of 1,429 shares of Common Stock at $4.00 per share. |
| 11/18/2025 | Acquisition of 640 shares of Common Stock at $4.09 per share. |
| 11/19/2025 | Acquisition of 1,921 shares of Common Stock at a weighted average price of $4.08 per share. |
| 12/22/2025 | Vesting date for 1/3 of stock options granted on 12/22/2023. |
| 01/02/2026 | Vesting date for 11,501 stock options granted on 01/03/2023. |
| 01/21/2026 | Vesting date for 1/3 of stock options granted on 01/21/2025. |
| 01/21/2027 | Vesting date for 1/3 of stock options granted on 01/21/2025. |
| 12/23/2027 | Expiration date for 50,000 stock options granted on 12/23/2022. |
| 01/03/2028 | Expiration date for 50,000 stock options granted on 01/03/2023. |
| 12/22/2028 | Expiration date for 280,000 stock options granted on 12/22/2021 and 50,000 stock options granted on 12/22/2023. |
| 08/30/2029 | Expiration date for 26,243 stock options granted on 08/30/2019. |
| 12/20/2029 | Expiration date for 23,636 stock options granted on 12/20/2019. |
| 01/21/2030 | Expiration date for 50,000 stock options granted on 01/21/2025. |
Recommendation
buyThe significant open market purchases by a key insider, the Chairman and Co-CEO, indicate strong conviction in Cryo-Cell International's current valuation and future growth potential. Such insider buying often precedes positive company developments and suggests that management believes the stock is undervalued, making it an attractive 'buy' signal for seasoned investors.
Keywords
Cryo-Cell International, CCEL, Insider Buying, Form 4, Stock Purchase, David Portnoy, Co-CEO, Director, 10% Owner, Common Stock, Stock Options, Beneficial Ownership, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.